

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF      Art Unit: 1611  
Küsters, Ernst et al.      Examiner: Klinkel, Kortney L.  
INTERNATIONAL APPLICATION NO: PCT/EP2004/011567  
FILED: October 14, 2004  
U.S. APPLICATION NO: 10/575827  
35 USC §371 DATE: April 14, 2006  
FOR: AMINOALKANOL DERIVATIVES

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☒ supplemental to the Information Disclosure Statement filed April 9, 2008.
- ☐ within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required.
- ☐ before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

- ☐ The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/011567, copies are not enclosed herewith.
- ☒ Copies of the references are enclosed herewith.
- ☐ Some of the non-asterisked references were cited in a search report in a corresponding application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-1202

Respectfully submitted,

  
Jennifer C. Chapman  
Attorney for Applicant  
Reg. No. 47,487

Date: *November 20, 2009*